| Name | Title | Contact Details |
|---|
Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules. In the near term, Pareto will introduce “designer molecules” as cosmetics, flavors and fragrances including molecules with properties unlike anything previously experienced. In the long term, Pareto’s molecules will be designed to enhance nutraceuticals, pharmaceuticals, and industrial commodities. Pareto’s potential is limitless. Join us as we ignite a molecular revolution
Merck Millipore is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GenPrime is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ActaCell is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.